FDA Approves Eli Lilly's GLP-1 Pill, Boosting Weight Loss Drug Market

• Foundayo showed 12.4% average weight loss compared to Zepbound's 20%+ results, but can be taken anytime without restrictions (unlike Novo's Wegovy pill which requires morning dosing on empty stomach)
• Analysts project Foundayo sales of $14.79 billion by 2030, compared to $24.68 billion for Zepbound and $44.87 billion for Mounjaro
• Lilly expects approval in 40+ countries within a year and has invested over $55 billion in manufacturing since 2020; Medicare patients will access the drug for $50/month starting this summer

FDA Approves Eli Lilly's GLP-1 Weight Loss Pill

Key Development:

The FDA has approved Eli Lilly's once-daily GLP-1 pill, Foundayo (orforglipron), marking a significant milestone in the weight loss drug market. The pill begins shipping Monday through LillyDirect, with pharmacy and telehealth availability following shortly.

Pricing and Accessibility:

• Insured patients: $25/month with coupon
• Out-of-pocket: $149-$349 depending on dosage
• Medicare patients: $50/month starting summer 2026
• Lowest dose matches Novo Nordisk's competing Wegovy pill at $149

Efficacy Comparison:

Foundayo demonstrates approximately 12.4% average weight loss versus Lilly's injectable Zepbound (20%+ weight loss) and Novo's Wegovy pill (16.6%). Despite lower efficacy, Lilly touts convenience advantages—Foundayo can be taken anytime without restrictions, unlike Wegovy's morning-only, empty-stomach requirement.

Market Positioning:

Analysts project Foundayo sales reaching $14.79 billion by 2030, compared to $24.68 billion for Zepbound and $44.87 billion for Mounjaro. The pill's small-molecule formulation enables easier manufacturing and global scalability without cold-chain requirements. Lilly expects approval in 40+ countries within a year.

Strategic Context:

• Lilly acquired the molecule from Japan's Chugai in 2018 for $50 million upfront
• The company has invested $55+ billion in manufacturing since 2020
• Novo's Wegovy pill generated 600,000+ prescriptions in March, suggesting market expansion rather than cannibalization
• Lilly awaits crucial retatrutide data for its more potent obesity shot

Investment Implications:

A successful Foundayo launch is considered critical for Lilly's stock recovery from recent weakness, with analysts monitoring prescription trends closely.